HHS unveils plan to directly negotiate Medicare pharmaceutical prices
House Democrats passed a similar provision as part of a major drug pricing bill in 2019, although it never was enacted into law.
By Alan Goforth|September 13, 2021 at 12:02 PM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
The federal government would be able to directly negotiate the cost of pharmaceuticals under a plan announced last week by the Department of Health and Human Services. Under the proposal, the government would directly negotiate prices for drugs in Medicare parts B and D, with those prices also being available to private insurance plans and any employers who want to participate.
The plan, part of a $3.5 trillion reconciliation proposal, mirrors a range of legislative options that both House and Senate lawmakers have floated in recent years, “Politico” reported. These include capping out-of-pocket costs in Medicare Part D; limiting how quickly pharmaceutical companies can hike prices on existing drugs; and banning so-called pay-for-delay agreements aimed at blocking generic competition to brand-name drugs.
Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.
Your access to unlimited BenefitsPRO.com content isn’t changing. Once you are an ALM digital member, you’ll receive:
Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com